BAC and Octapharma to develop custom ligand for recombinant plasma protein
"We have proven that we can design ligands for almost any purification challenge," commented Laurens Sierkstra, CEO of BAC. "Our technology platform enables us to work with our partners to produce affinity media that is custom designed for each individual purification target, meaning that our customers can have absolute confidence that their purification process will be a success. We are very much looking forward to working with Octapharma on this project."
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.